Autism spectrum disorder (ASD) is a complicated neurodevelopmental disability with an increasing prevalence worldwide and considerable implications for individuals and their families.1-3 According to the Autism and Developmental Disabilities Monitoring Network, the prevalence of ASD in children aged 8 years was 2.30% in 2018, which was similar to the prevalence of 2.47% in 2014 to 2016 reported by Xu et al.2,4 The aim of the study was to estimate the ASD prevalence among children and adolescents in the US in 2019 and 2020.
We conducted a cross-sectional study using data from the National Health Interview Survey (NHIS), which collects information through household interviews using multistage stratified sampling.5 We used NHIS data from 2019 and 2020 because the questionnaire was redesigned in 2019. Information about ASD diagnosed by a physician or other health care professional was reported by a parent or guardian. The conditional sample child response rate was 90.53% in 2019 and 87.38% in 2020.
The Guangdong Pharmaceutical University Academic Review Board deemed the study exempt from review because only deidentified data were used. All respondents provided informed verbal consent before participation. The study followed the STROBE reporting guideline.
The weighted prevalence of ASD among children and adolescents in the US aged 3 to 17 years in 2019 and 2020 was calculated using survey weights, strata, and primary sampling units created by the National Center for Health Statistics to allow for national estimates according to NHIS analytic guidelines (https://www.cdc.gov/nchs/nhis/methods.htm). The trends in the prevalence from 2014 to 2020 were also examined. All statistical analyses were performed using SAS, version 9.4 (SAS Institute, Inc). Two-sided P < .05 was considered to be statistically significant.
Of 12 554 individuals aged 3 to 17 years (6430 [51.22%] boys, 6124 [48.78%] girls), 410 were reported to have a diagnosis of ASD in 2019 and 2020. The prevalence of ASD was 2.79% (95% CI, 2.34%-3.24%) in 2019, 3.49% (95% CI, 2.82%-4.15%) in 2020, and 3.14% (95% CI, 2.73%-3.54%) in 2019 and 2020 overall. A significant difference in prevalence was observed between sexes (4.64% [95% CI, 3.99%-5.29%] in boys vs 1.56% [95% CI, 1.16%-1.97%] in girls; P < .001) and in family income to poverty ratio (<1.00, 4.89% [95% CI, 3.44%-6.34%]; 1.00-1.99, 2.71% [95% CI, 1.93%-3.49%]; 2.00-3.99, 3.20% [95% CI, 2.54%-3.85%]; and ≥4.00, 2.45% [95% CI, 1.86%-3.04%]; P < .001) (Table). The weighted prevalence of ASD increased from 2.24% (95% CI, 1.89%-2.59%) in 2014 to 3.49% (95% CI, 2.82%-4.15%) in 2020 (P for trend = .31) (Figure).
Using nationally representative data in the US, the estimated ASD prevalence was 3.14% among children and adolescents in the US in 2019 and 2020. This finding was higher than the reported prevalence from the NHIS in 2014 to 2016 (2.47%),2 Autism and Developmental Disabilities Monitoring Network in 2018 (2.30%),4 and National Survey of Children’s Health in 2016 (2.50%).3 The estimated prevalence was also higher than that reported in other countries and geographical areas in previous years. Chiarotti and Venerosi6 reviewed ASD prevalence estimates published since 2014, which ranged from 0.42% to 3.13% in Europe, 0.11% to 1.53% in the Middle East, and 1.41% to 2.52% in Australia. The prevalence of ASD is higher in boys than in girls, and a significant difference was found in children with different family economic status in this study. We found the prevalence of ASD increased from 2014 to 2016, decreased from 2016 to 2017, and then increased again from 2017 to 2020.
A limitation of this study was that information provided by parents or guardians may be affected by recall bias. Given that ASD is a lifelong disease in most children, future research needs to focus on understanding risk factors for and causes of ASD.
Accepted for Publication: March 1, 2022.
Published Online: July 5, 2022. doi:10.1001/jamapediatrics.2022.1846
Corresponding Authors: Wenhan Yang, MD, PhD, Department of Child and Adolescent Health, School of Public Health, Guangdong Pharmaceutical University, 283 Jianghai Rd, G726 of SPH Bldg, Guangzhou, Guangdong Province, 510006, China (wenhan-yang@gdpu.edu.cn); Guifeng Xu, MD, PhD, Department of Pediatrics, The First Affiliated Hospital, University of Science and Technology of China, 17 Lujiang Rd, Luyang District, Hefei, Anhui Province, 230001, China (xguifeng365@ustc.edu.cn).
Author Contributions: Dr Yang had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Mss Q. Li and Y. Li contributed equally to this work.
Concept and design: Q. Li, Y. Li, Chen, Xing, Xu, Yang.
Acquisition, analysis, or interpretation of data: Q. Li, Y. Li, Liu, Xu, Yang.
Drafting of the manuscript: Q. Li, Y. Li.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Q. Li, Y. Li, Xing, Xu, Yang.
Obtained funding: Yang.
Administrative, technical, or material support: Chen, Yang.
Supervision: Liu, Xing, Xu, Yang.
Conflict of Interest Disclosures: None reported.
4.Maenner
MJ, Shaw
KA, Bakian
AV,
et al. Prevalence and characteristics of autism spectrum disorder among children aged 8 years—Autism and Developmental Disabilities Monitoring Network, 11 sites, United States, 2018.
MMWR Surveill Summ. 2021;70(11):1-16. doi:
10.15585/mmwr.ss7011a1PubMedGoogle ScholarCrossref 5.Parsons
VL, Moriarity
C, Jonas
K, Moore
TF, Davis
KE, Tompkins
L. Design and estimation for the National Health Interview Survey, 2006-2015.
Vital Health Stat 2. 2014;(165):1-53.
PubMedGoogle Scholar